The TEL-AML1 leukemia fusion gene dysregulates the TGF-β pathway in early B lineage progenitor cells

Journal of Clinical Investigation

Volumn 119, Issue 4, 2009, Pages 826-836

  Ford, Anthony M ^a   Palmi, Chiara ^a,b,c   Bueno, Clara ^a,d   Hong, Dengli ^e   Cardus, Penny ^a   Knight, Deborah ^a   Cazzaniga, Giovanni ^b   Enver, Tariq ^e   Greaves, Mel ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b SAN GERARDO HOSPITAL   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d UNIVERSITY OF GRANADA   (Spain)

^e JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA; SMAD3 PROTEIN; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR RUNX1; CDKN1B PROTEIN, MOUSE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; ONCOPROTEIN; SMAD PROTEIN; TEL AML1 FUSION PROTEIN; TEL-AML1 FUSION PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ARTICLE; CELL GROWTH; CELL LINEAGE; CELL PROLIFERATION; CELL TYPE; CONTROLLED STUDY; FUSION GENE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE TARGETING; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOREGULATION; LYMPHOCYTE COUNT; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PHENOTYPE; PRE B LYMPHOCYTE; PRELEUKEMIA; PRIORITY JOURNAL; PROTEIN BINDING; SIGNAL TRANSDUCTION; STEM CELL EXPANSION; TRANSGENE; UMBILICAL CORD BLOOD; ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL; BIOLOGICAL MODEL; CANCER STEM CELL; CELL LINE; CYTOLOGY; FETUS BLOOD; GENE FUSION; GENETIC TRANSFECTION; GENETICS; HEMATOPOIESIS; METABOLISM; PATHOLOGY; STEM CELL;

ANIMALS; CELL LINE; CELL PROLIFERATION; CORE BINDING FACTOR ALPHA 2 SUBUNIT; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FETAL BLOOD; GENE EXPRESSION; HEMATOPOIESIS; HUMANS; MICE; MODELS, BIOLOGICAL; NEOPLASTIC STEM CELLS; ONCOGENE FUSION; ONCOGENE PROTEINS, FUSION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRECURSOR CELLS, B-LYMPHOID; SIGNAL TRANSDUCTION; SMAD PROTEINS; STEM CELLS; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 65249178875     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI36428     Document Type: Article

References (63)

1. Romana, S.P., et al. 1995. High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia. Blood. 86:4263-4269.
2. Golub, T.R., et al. 1995. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. U. S. A. 92:4917-4921.
3. Shurtleff, S.A., et al. 1995. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia. 9:1985-1989.
4. Mori, H., et al. 2002. Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc. Natl. Acad. Sci. U. S. A. 99:8242-8247.
5. Greaves, M.F., Maia, A.T., Wiemels, J.L., and Ford, A.M. 2003. Leukemia in twins: lessons in natural history. Blood. 102:2321-2333.
6. Tsuzuki, S., Seto, M., Greaves, M., and Enver, T. 2004. Modelling first-hit functions of the t(12;21) TEL-AML1 translocation in mice. Proc. Natl. Acad. Sci. U. S. A. 101:8443-8448.
7. Morrow, M., Horton, S., Kioussis, D., Brady, H.J.M., and Williams, O. 2004. TEL-AML1 promotes development of specific hematopoietic lineages consistent with preleukemic activity. Blood. 103:3890-3896.
8. Fischer, M., et al. 2005. Defining the oncogenic function of the TEL/AML1 (ETV6/RUNX1) fusion protein in a mouse model. Oncogene. 24:7579-7591.
9. Andreasson, P., Schwaller, J., Anastasiadou, E., Aster, J., and Gilliland, D.G. 2001. The expression of ETV6/CBF2 (TEL/AML1) is not sufficient for the transformation of hematopoietic cell lines in vitro or the induction of hematologic disease in vivo. Cancer Genet. Cytogenet. 130:93-104.
10. Greaves, M.F., and Wiemels, J. 2003. Origins of chromosome translocations in childhood leukaemia. Nat. Rev. Cancer. 3:639-649.
11. Greaves, M. 2006. Infection, immune responses and the aetiology of childhood leukaemia. Nat. Rev. Cancer. 6:193-203.
12. Mullighan, C.G., et al. 2007. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 446:758-764.
13. Hong, D., et al. 2008. Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science. 319:336-339.
14. Speck, N.A., and Gilliland, D.G. 2002. Core-binding factors in haematopoiesis and leukaemia. Nat. Rev. Cancer. 2:502-513.
15. Hiebert, S.W., et al. 1996. The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription. Mol. Cell. Biol. 16:1349-1355.
16. Guidez, F., et al. 2000. Recruitment of the nuclear receptor corepressor N-CoR by the TEL moiety of the childhood leukemia-associated TEL-AML1 oncoprotein. Blood. 96:2557-2561.
17. Vignali, D.A.A., Collinson, L.W., and Workman, C.J. 2008. How regulatory T cells work. Nat. Rev. Immunol. 8:523-532.
18. Massagué, J., Blain, S.W., and Lo, R.S. 2000. TGFβ signaling in growth control, cancer, and heritable disorders. Cell. 103:295-309.
19. Ichii, M., et al. 2008. Regulation of human B lymphopoiesis by the transforming growth factor-β superfamily in a newly established coculture system using human mesenchymal stem cells as a supportive microenvironment. Exp. Hematol. 36:587-597.
20. Wang, Y., O'Malley, B.W., Jr., Tsai, S.Y., and O'Malley, B.W. 1994. A regulatory system for use in gene transfer. Proc. Natl. Acad. Sci. U. S. A. 91:8180-8184.
21. Palacios, R., and Steinmetz, M. 1985. IL3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell. 41:727-734.
22. Mahmud, N., et al. 1999. Possible involvement of bcl-2 in regulation of cell-cycle progression of haemopoietic cells by transforming growth factor-1. Br. J. Haematol. 105:470-477.
23. Kamesaki, H., Nishizawa, K., Michaud, G.Y., Cossman, J., and Kiyono, T. 1998. TGF-β1 induces the cyclin-dependent kinase inhibitor p27Kip1 mRNA and protein in murine B cells. J. Immunol. 160:770-777.
24. Lin, Y.C., and Stavnezer, J. 1992. Regulation of transcription of the germ-line Ig alpha constant region gene by an ATF element and by novel transforming growth factor-beta 1 responsive elements. J. Immunol. 149:2914-2925.
25. Dennler, S., et al. 1998. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J. 17:3091-3100.
26. Inman, G.J., et al. 2002. SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 62:65-74.
27. Jakubowiak, A., et al. 2000. Inhibition of the transforming growth factor β1 signaling pathway by the AML1/ETO leukemia-associated fusion protein. J. Biol. Chem. 275:40282-40287.
28. Mitani, K. 2004. Molecular mechanisms of leukemogenesis by AML1/EVI-1. Oncogene. 23:4263-4269.
29. Pardali, E., et al. 2000. Smad and AML proteins synergistically confer transforming growth factor beta1 responsiveness to human germ-line IgA genes. J. Biol. Chem. 275:3552-3560.
30. Ford, A.M., Watt, S.M., Furley, A.J.W., Molgaard, H.V., and Greaves, M.F. 1988. Cell lineage specificity of chromatin configuration around the immunoglobulin heavy chain enhancer. EMBO J. 7:2393-2399.
31. Bernardin, F., et al. 2002. TEL-AML1, expressed from t(12;21) in human acute lymphocytic leukemia, induces acute leukemia in mice. Cancer Res. 62:3904-3908.
32. Rumfelt, L.L., Zhou, Y., Rowley, B.M., Shinton, S.A., and Hardy, R.A. 2006. Lineage specification and plasticity in CD19- early B cell precursors. J. Exp. Med. 203:675-687.
33. Mishra, L., Derynck, R., and Mishra, B. 2005. Transforming growth factor-β signaling in stem cells and cancer. Science. 310:68-71.
34. Schmidt-Weber, C.B., and Blaser, K. 2004. Regulation and role of transforming growth factor-β in immune tolerance induction and inflammation. Curr. Opin. Immunol. 16:709-716.
35. Siegel, P.M., and Massagué, J. 2003. Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nat. Rev. Cancer. 3:807-821.
36. Bierie, B., and Moses, H.L. 2006. TGFβ: the molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer. 6:506-520.
37. Wang, D., et al. 2000. Analysis of specific gene mutations in the transforming growth factor-β signal transduction pathway in human ovarian cancer. Cancer Res. 60:4507-4512.
38. Gomis, R.R., Alarcón, C., Nadal, C., Van Poznak, C., and Massagué, J. 2006. C/EBPβ at the core of the TGFβ cytostatic response and its evasion in metastatic breast cancer cells. Cancer Cell. 10:203-214.
39. Ito, Y., and Miyazono, K. 2003. RUNX transcription factors as key targets of TGF-β superfamily signaling. Curr. Opin. Genet. Dev. 13:43-47.
40. Flavell, J.R., et al. 2008. Down-regulation of the TGF-beta target gene, PTPRK, by the Epstein-Barr virus encoded EBNA1 contributes to the growth and survival of Hodgkin lymphoma cells. Blood. 111:292-301.
41. Lin, H.-K., Bergmann, S., and Pandolfi, P.P. 2005. Deregulated TGF-β signaling in leukemogenesis. Oncogene. 24:5693-5700.
42. Dong, M., and Blobe, G.C. 2006. Role of transforming growth factor-β in hematologic malignancies. Blood. 107:4589-4596.
43. Sood, R., Talwar-Trikha, A., Chakrabarti, S.R., and Nucifora, G. 1999. MDS1/EVI1 enhances TGF-β1 signaling and strengthens its growth-inhibitor effect, but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-β1. Leukemia. 13:348-357.
44. DeCoteau, J.F., et al. 1997. Loss of functional cell surface transforming growth factor β (TGF-β) type 1 receptor correlates with insensitivity to TGF-β in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U. S. A. 94:5877-5881.
45. Kurokawa, M., et al. 1998. The t(3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-β-mediated growth inhibition of myeloid cells. Blood. 92:4003-4012.
46. Ford, A.M., et al. 1998. Fetal origins of the TELAML1 fusion gene in identical twins with leukemia. Proc. Natl. Acad. Sci. U. S. A. 95:4584-4588.
47. Wiemels, J.L., et al. 1999. Prenatal origin of acute lymphoblastic leukaemia in children. Lancet. 354:1499-1503.
48. Diakos, C., et al. 2007. RNAi-mediated silencing of TEL/AML1 reveals a heat-shock protein- and survivin-dependent mechanism for survival. Blood. 109:2607-2610.
49. Einav, U., et al. 2005. Gene expression analysis reveals a strong signature of an interferon-induced pathway in childhood lymphoblastic leukemia as well as in breast and ovarian cancer. Oncogene. 24:6367-6375.
50. Cavé, H., et al. 1997. ETV6 is the target of chromosome 12p deletions in t(12;21) childhood acute lymphoblastic leukemia. Leukemia. 11:1459-1464.
51. Balkwill, F. 2004. Cancer and the chemokine network. Nat. Rev. Cancer. 4:540-550.
52. Meira, L.B., et al. 2008. DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J. Clin. Invest. 118:2516-2525.
53. Mullighan, C.G., et al. 2008. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 453:110-114.
54. Pasqualucci, L., et al. 2008. AID is required for germinal center-derived lymphomagenesis. Nat. Genet. 40:108-112.
55. Dao, M.A., Taylor, N., and Nolta, J.A. 1998. Reduction in levels of the cyclin-dependent kinase inhibitor p27(kip-1) coupled with transforming growth factor beta neutralization induces cell-cycle entry and increases retroviral transduction of primitive human hematopoietic cells. Proc. Natl. Acad. Sci. U. S. A. 95:13006-13011.
56. Karasuyama, H., and Melchers, F. 1988. Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using a modified cDNA expression vectors. Eur. J. Immunol. 18:97-104.
57. Demaison, C., et al. 2002. High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of immunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum. Gene Ther. 13:803-813.
58. Guenechea, G., et al. 2000. Transduction of human CD34+ CD38- bone marrow and cord bloodderived SCID-repopulating cells with third-generation lentiviral vectors. Mol. Ther. 1:566-573.
59. Piacibello, W., et al. 1999. Engraftment in nonobese diabetic severe combined immunodeficient mice of human CD34(+) cord blood cells after ex vivo expansion: evidence for the amplification and self-renewal of repopulating stem cells. Blood. 93:3736-3749.
60. Ailles, L., et al. 2002. Molecular evidence of lentiviral vector-mediated gene transfer into human self-renewing, multi-potent, long-term NOD/ SCID repopulating hematopoietic cells. Mol. Ther. 6:615-626.
61. Nishihara, M., et al. 1998. A combination of stem cell factor and granulocyte colony-stimulating factor enhances the growth of human progenitor B cells supported by murine stromal cell line MS-5. Eur. J. Immunol. 28:855-864.
62. Ohkawara, J.I., et al. 1998. Culture system for extensive production of CD19+IgM+ cells by human cord blood CD34+ progenitors. Leukemia. 12:764-771.
63. Cooper, M.D., Mulvaney, D., Coutinho, A., and Cazenave, P.-A. 1986. A novel cell surface molecule on early B-lineage cells. Nature. 321:616-618.